Announcement on holding the results briefing for the first quarter of 2023 and 2024
Announcement on By-election of Independent Directors of the 2nd Board of Directors and Members of the Special Committee of the Board
Independent Director Candidate Statements and Commitments
Independent Director Nominee Statements and Commitments
Nomination Committee's review opinions on independent director candidates
Notice on convening the 2023 Annual General Meeting of Shareholders
Announcement on the resignation of an independent director
Haitong Securities Co., Ltd. report on the 2023 continuous supervision site inspection report of Shanghai Bide Pharmaceutical Technology Co., Ltd.
Haitong Securities Co., Ltd.'s 2023 Continuous Supervision Annual Follow-up Report on Shanghai Bide Pharmaceutical Technology Co., Ltd.
Announcement on the progress of the repurchase of shares through centralized bidding transactions
Shanghai Bide Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (April 26, 2024)
Summary of Bide Pharma's 2023 Annual Report
2023 ANNUAL REPORT
2023 Audit Report
Special review instructions for non-operating capital occupation and other related capital transactions
Announcement on the Company and its wholly-owned subsidiaries applying for comprehensive credit lines and providing guarantees in 2024
2023 Internal Control Evaluation Report
Announcement on the 2023 Profit Distribution Plan
Independent Director's Debriefing Report-Liu Zhichang
2023 Internal Control Audit Report
No Data